Clinical efficacy of ibrutinib + R-CHOP in untreated, non-GCB DLBCL co-expressing MYC and BCL2: subanalysis of the phase III PHOENIX trial

The Lymphoma Hub is excited to present a visual abstract representing key data from an exploratory analysis of the phase III PHOENIX trial (NCT01855750). This analysis examined the clinical impact of ibrutinib plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in newly diagnosed patients with non-germinal center B-cell type diffuse large B-cell lymphoma highly co-expressing BCL2 and MYC. Results from the phase III PHOENIX trial, previously reported on the Lymphoma Hub, showed that the addition of ibrutinib to R-CHOP did not improve survival in patients with previously untreated non-GCB diffuse large B-cell lymphoma.